 |
“We have saved a tremendous amount of paper pushing by using ExpenseWatch.com. We no longer have an employee walking purchase orders around the office for signatures – now everyone can simply log in and approve!”
Lin Moody,
Director, Finance & Administration |
About Novocell Inc.
|
|
Novocell Issues
- Efficiency: Novocell needed to make its requisition process as efficient
as possible. Time wasted pushing paper was a big problem.
- Company Size: As a small research and development company, Novocell
needed a cost-effective expense management system.
- Manual Processes: Prior to ExpenseWatch.com, Novocell used a proprietary
FileMaker database for its requisitions. Employees tracked down signature
approvals manually.
Operating Expense Goals
- Paperless Systems: Novocell needed to create an efficient process
to track procurement procedures. Eliminating the paper trail and handling
net purchasing more efficiently was paramount. The company wanted to simplify
the entire process to flow as smoothly as possible.
- Improved Requisition Process: Novocell wanted a system that would
allow it to submit an electronic requisition and check the status online.
Submitting and reviewing requisitions needed to consume less time and money.
ExpenseWatch.com Solution
- Automation: Instead of filling out piles of paper forms, users
submit electronic requisitions and check the status online. This provides
far more information and reduces the time needed for reviews.
- Dynamic Solution with Automatic Upgrades: The ExpenseWatch.com
online infrastructure allows for new features and enhancements to be added without burdening Novocell with expensive upgrades.
About Novocell
Novocell is a private biotechnology company focused on developing cell replacement therapies for the treatment of human degenerative disease.
Novocell is developing a technology platform that has the potential to treat a wide range of human degenerative diseases—these include liver disease, Parkinson’s disease, macular degeneration and stroke.
The Company’s initial focus is on pancreatic islet transportation for the treatment of diabetes.
< Complete case studies list | top ^